期刊文献+

基底节、黑质的MRI体积测量在帕金森病中的应用研究 被引量:11

MRI-Based Volumetric Analysis of Basal Ganglia Nuclei and Substantia Nigra in Patients with Parkinson’s Disease
暂未订购
导出
摘要 目的:探讨MRI体积测量在帕金森病形态学改变上的意义,及在早期诊断上的作用。材料和方法:利用3T磁共振成像系统对帕金森病病人和正常对照组者分别进行3D-FSPGR的T1WI序列,FSE的PDWI/T2WI序列的扫描。其中早期PD病人16例,晚期PD病人8例,正常对照组8例。通过三维容积重建的方法测量出全脑体积、双侧尾状核、壳核、苍白球,以及黑质的体积,并对体积值进行标化处理。比较分析早期PD组,晚期PD组,对照组三组之间的差异。结果:PD病人的全脑体积和正常人无差异(P>0.05),早期和晚期帕金森病的壳核体积均小于正常人(P<0.05),减小程度分别为12.5%和26.5%。晚期PD的壳核体积较早期PD减小了16.0%(P=0.002)。晚期PD组苍白球体积较对照组下降19.2%(P=0.023)。尾状核、黑质体积在对照组、早晚期PD组中无显著差别(P>0.05)。结论:早和晚期PD的壳核,晚期PD的苍白球形态上已出现萎缩,尾状核,黑质没有明显萎缩。壳核的体积测量可能为早期PD的诊断提供一种有效的方法。 Purpose: To evaluate the ability of MRI - based volumetry to detect the changes of morphology in Parkinson's disease(PD), and to explore the value of volumetric measurement for the diagnosis of PD in early stage. Materials and Methods: 16 patients with early stage PD, 8 patients with advanced PD, and 8 normal controls had been scanned with 3D - FSPGR and FSE sequences by 3T MR. The volumes of caudate, putamen, globus pallidus, substatia nigra of both sides, and total brain were measured on 3 - dimensional reconstructed imagings. Results:. Patients with PD had no significantly reduced total brain volume (P 〉 0.05). The putamen volume was significantly diminished in both early stage PD and advanced PD compared with that in controls (P〈 0.05), and the percentage of atrophy was 12.5% and 26.5%, respectively. The reduced volume of globns pallidns was detected only in advanced PD(P 〈 0.05). There were no significant differences in total brain, caudate, or substatia nigra between early stage PD , advanced PD, and controls. Conclusion: MRI - based volumetry can provide more useful information about PD in vivo. The volumetric measurement of putamen could possibly be a useful method for diagnosis of PD in early stage.
出处 《中国医学计算机成像杂志》 CSCD 2006年第1期6-10,共5页 Chinese Computed Medical Imaging
关键词 帕金森病 磁共振成像 体积测量 Parkinson disease Magnetic resonance imaging Volumetric measurement
  • 相关文献

参考文献16

  • 1Lisanby SH,McDonald WM,Massey EW,et al.Diminished subcortical nuclei volumes in Parkinson's disease by MR imaging.J Neural Transm Suppl,1993,40:13 ~ 21
  • 2Hu MT,White SJ,Chaudhuri KR,et al.Correlating rates of cerebral atrophy in Parkinson's disease with measures of cognitive decline.J Neural Transm,2001,108:571 ~ 580
  • 3Schulz JB,Skalej M,Wedekind D,et al.Magnetic resonance imaging - based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy.Ann Neurol,1999,45:65 ~ 74
  • 4Ghaemi M,Hilker R,Rudolf J,et al.Differentiating multiple system atrophy from Parkinson's disease:contribution of striatal and midbrain MRI volumetry and multi - tracer PET imaging.J Neurol Neurosurg Psychiatry,2002,73:517 ~ 523
  • 5徐德隆 陈生弟 刘振国 等.帕金森病临床新技术[M].北京:人民军医出版社,2002.18.
  • 6Almeida OP,Burton EJ,McKeith I,et al.MRI study of caudate nucleus volume in Parkinson's disease with and without dementia with Lewy bodies and Alzheimer's disease.Dement Geriatr Cogn Disord,2003,16:57 ~ 63
  • 7Luft AR,Skalej M,Welte D,et al.Reliability and exactness of MRI - based volumetry:a phantom study.J Magn Reson Imaging,1996,6:700 ~ 704
  • 8O'Neill J,Sshuff N,Marks,WJ,et al.Quantitative ^1H magnetic resonance spectroscopy and MRI of Parkinson's disease.Mov Disord,2002,17:917 ~ 927
  • 9王坚,蒋雨平,项景德,陈正平,管一晖,赵军,苏惠琳,郭丽萍,杨莉芹,邬剑军,丁正同.^(18)F-FP-β-CIT PET脑显像在早期诊断帕金森病中的意义[J].中华核医学杂志,2003,23(4):216-218. 被引量:24
  • 10Kempster PA,Gibb WR,Stern,GM,et al.Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations.J Neurol Neurosurg Psychiatry,1989,52:72~ 76

二级参考文献19

  • 1王新德.帕金森病及帕金森综合征的诊断标准和鉴别诊断[J].中华神经精神科杂志,1985,18(4):256-256.
  • 2Kempster PA, Gibb WR, Stem GM, et al. Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related mootor fluctuations. J Neurol Neurosurg Psychiatry, 1989, 52:72-76.
  • 3Brooks DJ. Monitoring neuroprotection and restorative therapies in Parkinson's disease with PET. J Neural Transm, 2000, 60 Suppl: 125-137.
  • 4Brooks DJ. Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann Neurol, 2003, 53: S110-S118.
  • 5Nurmi E, Raottinen H, Kaasinen V, et al. Progression in Parkinson's disease: a positron emission tomography study with a doparaine transporter ligand ^18F-CFT. Ann Neurol, 2000, 47: 804-808.
  • 6Ribeiro MJ, Vidailhet M, Loc'h C, et al. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol, 2002, 59: 580-586.
  • 7Hu MTM, Taylor-Robinson SD, Chaudhuri KR, et al. Cortical dysfunction in non-demented Parkinson's disease peients: a combined ^31P-MRS and ^18F-FDG-PET study. Brain, 2000, 123: 340-352.
  • 8Eidelberg D, Moeller JR, Ishikawa T, et al. Assessment of disease severity in Parkinsonism with ^18F-fluoradeoxyglucose and PET. J Nucl Med,1995, 36: 378-383.
  • 9Chaly T, Dhawan V, Kazumata K, et al. Radiosynthesis of ^18F-N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl) nortropane and the first human study with positron emission tomography. Nucl Med Biol, 1996,23: 999-1004.
  • 10Kazumata K, Dhawan V, Chaly T, et al. Dopamine transporter imaging with ^18F-FPCIT and PET. J Nucl Med, 1998, 39: 1521-1530.

共引文献57

同被引文献46

引证文献11

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部